BiotechTube
Home/REVOLUTION Medicines/Mark A. Goldsmith, M.D., Ph.D.
MA

Mark A. Goldsmith, M.D., Ph.D.

President, Chief Executive Officer & Chairman

REVOLUTION Medicines

Therapeutic Areas

Oncology

REVOLUTION Medicines Pipeline

DrugIndicationPhase
RMC-4630RAS-addicted cancers (SHP2 inhibitor)Phase 1/2
RMC-6236KRASG12X mutant solid tumors (Pan-RAS)Phase 1/2
RMC-6291KRASG12C mutant solid tumorsPhase 1/2
RMC-9805KRASG12D mutant solid tumorsPhase 1
RMC-8839KRASG13C mutant solid tumorsPhase 1

Leadership Team at REVOLUTION Medicines

ZS
Zachary S. Hornby
Chief Operating Officer
MA
Margaret A. Hornbach
Chief Business Officer
JO
James O. Buss, Ph.D.
Chief Development Officer
SK
Steve Kelsey, M.D., FRCP, FRCPath
President, Research & Development
AL
Andrew L. Phillips, Ph.D.
Chief Scientific Officer
BA
Barbara A. Wood
Chief Legal Officer & Corporate Secretary
EM
Evan M. Kearns
Chief Accounting Officer
View full REVOLUTION Medicines profile